Vericel to Report Third Quarter 2026 Financial Results on November 5, 2026GlobeNewsWire · 2 days ago
Vericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha · Sep 15, 2026
Vericel: MACI And Regenerative Knee CartilageSeeking Alpha · Sep 14, 2026
Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026GlobeNewsWire · Sep 8, 2026
Canada Pension Plan Investment Board Takes Position in Vericel Corporation $VCELDefense World · Sep 2, 2026
Vericel Corporation $VCEL Shares Purchased by Bank of America Corp DEDefense World · Aug 15, 2026Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 30, 2026 | -$0.03 | $0.04 | Beat |
| May 7, 2026 | -$0.15 | -$0.12 | Beat |
| Feb 26, 2026 | $0.45 | $0.45 | Beat |
| Nov 6, 2025 | -$0.02 | $0.10 | Beat |
| Jul 31, 2025 | -$0.04 | -$0.01 | Beat |
| May 8, 2025 | -$0.09 | -$0.23 | Miss |